GSK Announces $10.6 Billion Acquisition of Nuvalent, Inc. for Oncology Expansion

Pharmaceutical giant GSK plc has agreed to acquire Nuvalent, Inc., a clinical-stage biopharmaceutical company, in a deal valued at $10.6 billion. This strategic acquisition aims to bolster GSK's oncology portfolio, particularly with two late-stage lung cancer inhibitors currently under US FDA review. These therapies are anticipated to receive potential approvals in 2026.